ONC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BeOne Medicines AG (ONC) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has a promising pipeline and recent regulatory approval in China, the lack of strong positive trading signals, mixed analyst ratings, and declining financial performance in the latest quarter suggest caution. Additionally, hedge fund selling and no significant insider activity further support a hold recommendation.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 73.838, and moving averages are converging, showing no clear trend. The stock is trading near its resistance level (R1: 320.617), suggesting limited immediate upside potential.
Conditional approval in China for lung cancer treatment tarlatamab.
Strong growth in gross margin (up 3.75% YoY).
Analysts note potential momentum from deal activity in the biotech sector.
Hedge funds are selling heavily, with a 7307.41% increase in selling over the last quarter.
Financial performance shows a significant drop in net income (-202.88% YoY) and EPS (-188.89% YoY).
Mixed analyst ratings with recent downgrades and lowered price targets.
No recent congress trading data or significant insider activity.
In Q3 2025, revenue increased by 41.00% YoY, but net income dropped significantly by -202.88% YoY. EPS also declined by -188.89% YoY, indicating profitability challenges. Gross margin improved slightly to 86.09%.
Analyst ratings are mixed. Truist lowered its price target to $411 from $412 but maintained a Buy rating. Wolfe Research initiated coverage with an Outperform rating and a $340 price target. Jefferies downgraded the stock to Hold with a $290 price target, citing that the stock is fairly priced at current levels. Other analysts have raised price targets slightly but remain cautious about growth prospects.
